Business
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License
About this update from Catalyst Pharmaceuticals, Inc.
[{"type":"text","content":"AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for Duchenne Muscular Dystrophy and Other Potential Indications Novel Corticosteroid With Favorable Side Effect Profile Catalyst Expects to Commercially Launch AGAMREE in Q1 2024 AGAMREE Comprehensive Patient Assistance Program to Help Ensure Affordable Access for All DMD Patients Upon Commercial Launch CORAL GABLES, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (\"Catalyst\" or \"Company\") (Nasdaq: CPRX) today reported that Santhera Pharmaceuticals (\"Santhera\") has obtained U.S. Food and Drug Administration (\"FDA\") approval for AGAMREE® (vamorolone) oral suspension 40 mg/mL for use in treating Duchenne Muscular Dystrophy (\"DMD\") in patients aged two years and older. AGAMREE offers a novel corticosteroid treatment option for DMD, addressing a significant unmet medical need. In July 2023, Catalyst secured the exclusive North American license and commercial rights for AGAMREE from Santhera for DMD and other potential indications, bolstering its neuroscience commercial portfolio with a highly synergistic neuromuscular asset. As part of that transaction, Santhera will promptly transfer the approved New Drug Application for AGAMREE to Catalyst. FDA’s approval of AGAMREE® was based on the data from the pivotal Phase 2b VISION-DMD study as supplemented with safety information collected from three open-label studies, including extension studies. In these trials, AGAMREE was administered at doses ranging from 2 to 6 mg/kg/day, extending for a period of up to 48 months. Compared with current standard-of-care corticosteroids, this novel corticosteroid treatment exhibited comparable efficacy, with data suggesting a reduction in adverse events, notably related to bone health, growth trajectory, and behavior. “We strongly believe that this novel steroid has the transformational potential to make a significant difference for patients living with Duchenne Muscular Dystrophy and potentially other chronic inflammatory diseases. The approval of AGAMREE underscores the potential of reshaping the DMD treatment paradigm for this life-threatening rare disease. The addition of AGAMREE expands our rare neuromuscular disease portf...